Therapy News and Research

RSS

The sooner the better when it comes to HIV/AIDS treatment

New research into HIV/AIDS therapy has found that starting treatment with drugs for the AIDS virus may be better sooner than later as victims are more than 70% less likely to die when they started taking cocktails of HIV drugs earlier than currently recommended.

27 Oct 2008

Exercise-induced fatigue in muscular dystrophies, study points to potential new therapies

A University of Iowa study suggests that the prolonged fatigue after mild exercise that occurs in people with many forms of muscular dystrophy is distinct from the inherent muscle weakness caused by the disease.

26 Oct 2008

Simple gene-based blood test, quicker, more accurate evaluation for cystic fibrosis

Researchers at National Jewish Health have identified a simple gene-based blood test that more accurately and quickly measures cystic fibrosis patients' response to therapy than current tests.

26 Oct 2008

Even minimally symptomatic obstructive sleep apnea increases cardiovascular risk

People with even minimally symptomatic obstructive sleep apnea (OSA) may be at increased risk for cardiovascular disease because of impaired endothelial function and increased arterial stiffness, according to a study from the Oxford Centre for Respiratory Medicine in the UK.

26 Oct 2008

New molecules with many branches will help unleash potential of nanotechnology

Materials science and the pharmaceutical industry could soon be revolutionized by emerging nanotechnologies based on designer molecules with long complex tree-and branch structures. Such molecules offer almost limitless scope for design of bespoke compounds for specific applications in disease therapy, for novel materials such as resins, as well as electronic displays, and energy storage. Almost every field involving design and synthesis of chemical compounds will be transformed by the arrival of technologies allowing nanoscale design of these branched molecules, known as hyperbranched polymers.

26 Oct 2008

NanoVibronix receives FDA clearance for PainShield diathermy device

NanoVibronix, a medical device company, announced that the US Food and Drug Administration (FDA) has granted 510K clearance to market PainShield MD, a diathermy device used to treat pain. PainShield is the first hands-free, patch-based diathermy device, thus allowing for an entirely new dimension in ultrasound treatment of pain and soft tissue healing. The PainShield consists of a disposable patch connected to a portable reusable driver and generates ultrasound waves to the desired area of the body.

23 Oct 2008

Leukaemia drug may reverse multiple sclerosis brain damage

Scientists in Britain say a drug which was developed to treat leukaemia may also be a powerful new weapon against multiple sclerosis (MS).

23 Oct 2008

ZymoGenetics presents interim Interleukin 21 phase 2 results in renal cell cancer

ZymoGenetics, Inc. presented interim results today from a Phase 2 clinical trial evaluating Interleukin 21 (IL-21) in combination with Nexavar (sorafenib) tablets in patients with metastatic renal cell cancer.

22 Oct 2008

Medtronic launches new device to improve minimally-invasive treatment of thoracic aortic aneurysms

Extending an unmatched record of innovation in the field of endovascular aortic repair, Medtronic, Inc., today announced the U.S. market launch of the Talent Thoracic Stent Graft on the Xcelerant Delivery System, which makes minimally-invasive treatment of thoracic aortic aneurysms easier to perform.

22 Oct 2008

Gene study sheds new light on lung cancer

A multi-institution team, funded by the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH), today reported results of the largest effort to date to chart the genetic changes involved in the most common form of lung cancer, lung adenocarcinoma. The findings should help pave the way for more individualized approaches for detecting and treating the nation's leading cause of cancer deaths.

22 Oct 2008

Peregrine Pharmaceuticals reports on phase II trial of Bavituximab plus Docetaxel in advanced breast cancer

Peregrine Pharmaceuticals, Inc. has announced that updated preliminary data from the first stage of its Phase II trial evaluating bavituximab in combination with docetaxel showed that 10 of 14 (71%) evaluable breast cancer patients achieved an objective tumor response according to RECIST criteria.

22 Oct 2008

Aires Pharmaceuticals signs license agreement with NIH

Aires Pharmaceuticals Inc. today announced the signing of an exclusive license agreement with the U.S. National Institutes of Health for the patented use of a nitric oxide prodrug to treat cardiopulmonary conditions.

22 Oct 2008

Researchers identify novel type of antibody that potently inhibits HIV infection

A small antibody fragment that is highly effective in neutralizing the human immunodeficiency virus (HIV) by preventing the virus from entering cells has been identified by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).

21 Oct 2008

Laser treatment works well on sun-damaged skin

Researchers in the United States have found that sun-damaged skin responds well to laser treatment - which is good news for people with skin badly damaged by exposure to the sun.

21 Oct 2008

FDA grants orphan drug status to new 'Trojan Horse' like Ewing's Sarcoma drug

The Cure Our Children Foundation, a nonprofit charitable foundation dedicated to children, announced today that the U.S. Food and Drug Administration (FDA) has approved the Orphan Drug Designation of the foundation's unique drug product for children with Ewing's Sarcoma cancer. The efforts to develop this drug were made possible by the generous volunteers and researchers in private industry and at two universities.

20 Oct 2008

Sun-damaged skin responds well to laser treatment

Researchers at the University of Michigan Health System Department of Dermatology have found scientific evidence that the appearance of sun-damaged skin may be improved by treatment with a topical product that increases the skin's sensitivity to light, followed by laser therapy.

20 Oct 2008

FDA approves new labeling for psoriasis drug Raptiva

The U.S. Food and Drug Administration today announced labeling changes, including a Boxed Warning, to highlight the risks of life-threatening infections, including progressive multifocal leukoencephalopathy (PML), with the use of Raptiva (efalizumab). The labeling changes are based on the FDA's post-market surveillance.

19 Oct 2008

Genes that control cell death may play role in age-related hearing loss

Several genes that play a role in how our body's cells normally auto-destruct may play a role in age-related hearing loss, according to research published online in the journal Apoptosis - a journal devoted to the topic of cell suicide, or programmed cell death.

19 Oct 2008

Brain-derived neurotrophic factor may predict schizophrenia relapse

A factor that helps optimize brain formation and function may also provide clues about whether patients suffering with schizophrenia are headed toward relapse, researchers say.

16 Oct 2008

Biothera initiates second phase of metastatic colorectal cancer trial

Biothera has announced today it began dosing patients in the second arm of its metastatic colorectal cancer (mCRC) trial in August.

16 Oct 2008

Therapy News and Research

The sooner the better when it comes to HIV/AIDS treatment

Exercise-induced fatigue in muscular dystrophies, study points to potential new therapies

Simple gene-based blood test, quicker, more accurate evaluation for cystic fibrosis

Even minimally symptomatic obstructive sleep apnea increases cardiovascular risk

New molecules with many branches will help unleash potential of nanotechnology

NanoVibronix receives FDA clearance for PainShield diathermy device

Leukaemia drug may reverse multiple sclerosis brain damage

ZymoGenetics presents interim Interleukin 21 phase 2 results in renal cell cancer

Medtronic launches new device to improve minimally-invasive treatment of thoracic aortic aneurysms

Gene study sheds new light on lung cancer

Peregrine Pharmaceuticals reports on phase II trial of Bavituximab plus Docetaxel in advanced breast cancer

Aires Pharmaceuticals signs license agreement with NIH

Researchers identify novel type of antibody that potently inhibits HIV infection

Laser treatment works well on sun-damaged skin

FDA grants orphan drug status to new 'Trojan Horse' like Ewing's Sarcoma drug

Sun-damaged skin responds well to laser treatment

FDA approves new labeling for psoriasis drug Raptiva

Genes that control cell death may play role in age-related hearing loss

Brain-derived neurotrophic factor may predict schizophrenia relapse

Biothera initiates second phase of metastatic colorectal cancer trial

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News